ECYT Endocyte

Endocyte to Join the Russell 3000® Index

Endocyte to Join the Russell 3000® Index

WEST LAFAYETTE, Ind., June 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that its common stock has been selected for inclusion in the broad-market Russell 3000® Index following the Russell US Indices annual reconstitution, effective when the US markets open on Monday, June 25, 2018.

Russell US Indices are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes. Russell US Indexes are part of FTSE Russell, a leading global index provider.

Website Information

Endocyte routinely posts important information for investors on its website, , in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration-resistant prostate cancer (mCRPC). Endocyte also expects to have an Investigational New Drug application submitted in the fourth quarter of 2018 for its adaptor-controlled CAR T-cell therapy which will be initially studied in osteosarcoma. For additional information, please visit Endocyte's website at .

Investor Contact:

Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200

EN
25/06/2018

Underlying

ECYTEndocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Endocyte

 PRESS RELEASE
Free
ECYT ENDOCYTE

Endocyte Stockholders Approve Merger Agreement with Novartis AG

Endocyte Stockholders Approve Merger Agreement with Novartis AG WEST LAFAYETTE, Ind., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash. Approximately 99.8% of the votes cast at the meeting voted to a...

December 20, 2018 1 EN
 PRESS RELEASE
Free
ECYT ENDOCYTE

Endocyte Provides Third Quarter 2018 Financial Results and Operational...

Endocyte Provides Third Quarter 2018 Financial Results and Operational Update Entered into agreement and plan of merger with Novartis AG for $2.1Billion                WEST LAFAYETTE, Ind., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced financial results for the third quarter ended Sept. 30, 2018 and provided an operational update. “177Lu-PSMA-617’s value as a potential treatment for patients with mCRPC has been reinforced in both our regulatory interactio...

November 7, 2018 1 EN
 PRESS RELEASE
Free
ECYT ENDOCYTE

Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 ...

Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartis’ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that it has entered into an agreement and plan of merger with Novartis AG (“Novartis”) pursuant to which Novartis will acquire Endocyte for $24 per share, or a total equity value of ap...

October 18, 2018 1 EN
 PRESS RELEASE
Free
ECYT ENDOCYTE

Endocyte becomes first Purdue startup to reach $1.5B in value

Endocyte becomes first Purdue startup to reach $1.5B in value Endocyte’s primary cancer drug platforms include “two of the most exciting platforms in all of cancer right now.” One drug shows promising results in treating advanced prostate cancer and the other platform could improve treatment of pediatric bone cancer. West Lafayette, Ind., Oct. 03, 2018 (GLOBE NEWSWIRE) -- (Nasdaq: ECYT), reached a milestone this year when its value recently reached about $1.5 billion and as the company’s drug platforms continue to move through various clinical trials with promising results in treating a...

October 3, 2018 1 EN
Free Trial
ECYT ENDOCYTE

ENDOCYTE INCO. sees a downgrade to Slightly Negative on account of les...

The independent financial analyst theScreener just lowered the general evaluation of ENDOCYTE INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 2 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 2, 2018, the closing price was USD 17.22 and its targ...

10/03/18 October 3, 2018 6 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch